The short version of peptide research fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-12-21 and is reviewed periodically as new material appears.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
== See also == Phragmen's voting rules – a ballot load balancing method analogous to the idea of Archimedes' principle. Ship stability – Archimedes's theory of displacement of fluid is a core principle of ship stability. List of eponymous laws
The league's official statement concluded: "Reid strongly supports the AFL in its fundamental priority of looking after the health and welfare of players. He shares his concern over the serious circumstances which gave rise to the supplements saga at the Essendon Football Club ... The AFL accepts Dr Reid’s position and withdraws all charges against him, without penalty." Hird remained on the Essendon payroll and received his full salary during the suspension. The AFL initially demanded that the payments stopped when they were made public in December 2013 but acquiesced after determining that its legal position was weak. In Hird's absence, Mark Thompson stepped up to serve as senior coach in the 2014 season. At the time of the penalties for governance failures, no charges were laid against any players, whether or not banned substances had been used was unproven, and the ASADA and AFL investigation remained open.
In his psychological theory—which is not necessarily linked to a particular theory of social structure—the persona appears as a consciously created personality or identity, fashioned out of part of the collective psyche through socialisation, acculturation and experience. Jung applied the term persona because, in Latin, it means both personality and the masks worn by Roman actors of the classical period, expressive of the individual roles played. The persona, he argues, is a mask for the "collective psyche", a mask that 'pretends' individuality so that both self and others believe in that identity, even if it is really no more than a well-played role through which the collective psyche is expressed. It has also been referred to as the social archetype or the conformity archetype. Jung regarded the "persona-mask" as a complicated system that mediates between individual consciousness and the social community: it is "a compromise between the individual and society as to what a man should appear to be". But he also makes it quite explicit that it is, in substance, a character mask in the classical sense known to theatre, with its double function: both intended to make a certain impression on others and to hide (part of) the true nature of the individual, which he calls the 'shadow'. The therapist then aims to assist the individuation process through which the client (re)gains their "own self"—by liberating the self, both from the deceptive cover of the persona and from the power of unconscious impulses.
== Further reading == Shearer, Benjamin; Shearer, Barbara (1997). Notable women in the physical sciences : a biographical dictionary (1. publ. ed.). Westport, Conn. [u.a.]: Greenwood Press. ISBN 9780313293030. Busch-Vishniac, Ilene; Busch, Lauren; Tietjen, Jill (2024). "Chapter 12. Mary Engle Pennington". Women in the National Inventors Hall of Fame: The First 50 Years. Springer Nature. ISBN 9783031755255.
Graphene was properly isolated and characterized in 2004 by Andre Geim and Konstantin Novoselov at the University of Manchester. They pulled graphene layers from graphite with a common adhesive tape in a process called micro-mechanical cleavage, colloquially referred to as the Scotch tape technique. The graphene flakes were then transferred onto a thin silicon dioxide layer on a silicon plate ("wafer"). The silica electrically isolated the graphene and weakly interacted with it, providing nearly charge-neutral graphene layers. The silicon beneath the SiO2 could be used as a "back gate" electrode to vary the charge density in the graphene over a wide range. This work resulted in the two winning the Nobel Prize in Physics in 2010 for their groundbreaking experiments with graphene. Their publication and the surprisingly easy preparation method that they described, sparked a "graphene gold rush". Research expanded and split off into many different subfields, exploring different exceptional properties of the material—quantum mechanical, electrical, chemical, mechanical, optical, magnetic, etc.
Sources: en.wikipedia.org
In Italy, Gasparo Tagliacozzi (1546–1599), professor of surgery and anatomy at the University of Bologna, published Curtorum Chirurgia Per Insitionem (The Surgery of Defects by Implantations, 1597), a technico–procedural manual for the surgical repair and reconstruction of facial wounds in soldiers. The illustrations featured a re-attachment rhinoplasty using a biceps muscle pedicle flap; the graft attached at 3-weeks post-procedure; which, at 2-weeks post-attachment, the surgeon then shaped into a nose. In Great Britain, Joseph Constantine Carpue (1764–1846) published the descriptions of two rhinoplasties: the reconstruction of a battle-wounded nose, and the repair of an arsenic-damaged nose. (cf. Carpue's operation).
Single nucleotide polymorphisms (SNPs) in the MTRR gene impair MTR activity, resulting in elevated homocysteine levels due to compromised methylation to methionine. Elevated homocysteine levels are associated with birth defects in addition to pregnancy complications, cardiovascular disease, cancer, megaloblastic anemia, Alzheimer's diseases and cognitive dysfunction in the elderly. Presence of the mutant variant (66A>G) is associated with significantly lower, up to 4 fold, plasma cobalamin and folate levels in cardiac transplant patients. A consequent decrease in S-adenosylmethionine availability results in DNA hypomethylation. Low folate limits one carbon metabolism and homocysteine metabolism as vitamin B12 interacts with folate in this pathway. Additionally, this mutation is associated with an increased risk in type 2 diabetes.
Likewise, the Cohesin protein which binds sister chromatids in metaphase is able to be targeted by SUMOylation to allow the Cdc48 segregase to separate Cohesin and allow sister chromatid separation in early anaphase. In research as is often the case, scientists test drugs known to have significant effects on living systems; one such example is Rapamycin (known in pharmaceuticals as Sirolimus), the well-known inhibitor of mechanistic Target of Rapamycin, or mTOR. With respect to SUMOylation, Rapamycin may be thought of as having a "Sledge Hammer" effect, in which the drug promotes cellular autophagy, part of which includes broad-spectrum promotion of nonspecific SUMOylation for many proteins. This may be beneficial in some circumstances as it supports the breakdown of accumulated waste products. The importance of these studies in models such as yeast lies in their potential to inform scientists in the research and development of precise biomedical interventions that can translate to the improvement of human health in an array of clinical aspects.
=== Thin films === Gold nanoparticles capped with organic ligands, such as alkanethiol molecules, can self-assemble into large monolayers (>cm2). The particles are first prepared in organic solvent, such as chloroform or toluene, and are then spread into monolayers either on a liquid surface or on a solid substrate. Such interfacial thin films of nanoparticles have close relationship with Langmuir-Blodgett monolayers made from surfactants. The mechanical properties of nanoparticle monolayers have been studied extensively. For 5 nm spheres capped with dodecanethiol, the Young's modulus of the monolayer is on the order of GPa. The mechanics of the membranes are guided by strong interactions between ligand shells on adjacent particles. Upon fracture, the films crack perpendicular to the direction of strain at a fracture stress of 11
=== EC 1.6.7 With an iron–sulfur protein as acceptor (deleted sub-subclass) === EC 1.6.7.1: now EC 1.18.1.2 ferredoxin—NADP+ reductase EC 1.6.7.2: now EC 1.18.1.1 rubredoxin—NAD+ reductase EC 1.6.7.3: now EC 1.18.1.3 ferredoxin—NAD+ reductase
Sources: en.wikipedia.org
=== Accessory foramina === Accessory foramina are small openings, distinct from the main physiological foramen, which connect the root canal system to the periapical tissue through accessory canals. In micro-computed tomography (micro-CT) studies, they are often defined quantitatively, such as any apical foramen with a diameter smaller than 0.2 mm. Their prevalence varies significantly among different teeth. Research on mandibular canines found that approximately one-third of specimens had at least one accessory foramen. Studies of other tooth types confirm that accessory canals and their foramina are a common anatomical feature, especially in the apical region of roots. Due to their minute size, detailed visualization of accessory foramina is best achieved using high-resolution ex vivo imaging techniques like micro-CT, which is considered a gold standard for such morphological analysis.
These studies have produced models of protein adhesive and other biopolymer deteriorations and the concurrent pore system development. The reduction in bodily repair capability during aging is important to studies of senescence and age-associated disease, and allows the determination of age in living animals. Forensic science can use this technique to estimate the age of a cadaver or an objet d'art to determine authenticity.
== Niger, Chad, Benin, CAR == Amadou Boubacar Cissé – politician, former prime minister, former Minister of State for Planning, Regional Development, and Community Development, Niger Mamadou Tandja (Fula/Soninke)- former president, Niger Hama Amadou – politician, former prime minister and president of the National Assembly of Niger Amadou Cheiffou – politician, former prime minister of Niger Albadé Abouba – politician, former acting prime minister, Current Minister of State, Minister of Agriculture and Livestock. Niger Bibata Niandou Barry - former Minister of women Affairs. Salifou Modi - former chief of staff, Nigerien Army, Vice President of the National Council for the Safeguard of the Homeland (Military Junta). Aissa Diori - former first lady, Niger Amina Bazindre - former ambassador to romania, Hungary, Germany and Russia. Fatou Djibo - author, first Nigerian woman to drive a car. Bouli Ali Diallo - academic, activist. Abdou Abarry - Nigerian diplomat, former president united nations security council, special representative for Central Africa and Head of the United Nations Regional Office for Central Africa. Ide Oumarou - diplomat, government minister, and journalist, former secretary-general of the Organization of African Unity Abdel Kader Baba-Laddé (or General Baba Laddé or Mahamat Abdoul Kadre) – politician, Chad. Aïchatou Boulama Kané - first female governor of Niamey, former minister of foreign affairs.
PMID 30938236.{{cite journal}}: CS1 maint: multiple names: authors list (link) Acharya, B; Wang, K; Kim, IS; Kang, W; Moon, C; Lee, BH (2013). "In vivo imaging of myocardial cell death using a peptide probe and assessment of long-term heart function". Journal of Controlled Release. 172 (1): 367–73. doi:10.1016/j.jconrel.2013.08.294. PMID 24021357. Acharya, B; Chun, SY; Kim, SY; Moon, C; Shin, HI; Park, EK (2012). "Surface immobilization of MEPE peptide onto HA/β-TCP ceramic particles enhances bone regeneration and remodeling". Journal of Biomedical Materials Research Part B: Applied Biomaterials. 100 (3): 841–9. doi:10.1002/jbm.b.32648. PMID 22278974. Choi, YA; Lim, J; Kim, KM; Acharya, B; Cho, JY; Bae, YC; Shin, HI; Kim, SY; Park, EK (2010). "Secretome analysis of human BMSCs and identification of SMOC1 as an important ECM protein in osteoblast differentiation". Journal of Proteome Research. 9 (6): 2946–56. doi:10.1021/pr901110q. PMID 20359165. He, X; Bonaparte, N; Kim, S; Acharya, B; Lee, JY; Chi, L; Lee, HJ; Paik, YK; Moon, PG; Baek, MC; Lee, EK; KIM, JH; KIM, IS; Lee, BH (2012). "Enhanced delivery of T cells to tumor after chemotherapy using membrane-anchored, apoptosis-targeted peptide". Journal of Controlled Release. 162 (6): 521–8. doi:10.1016/j.jconrel.2012.07.023. PMID 22824781. Venkatesha, S. H.; Dudics, S; Acharya, B; Moudgil, K. D. (2014). "Cytokine-Modulating Strategies and Newer Cytokine Targets for Arthritis Therapy". International Journal of Molecular Sciences. 16 (1): 887–906. doi:10.3390/ijms16010887. PMC 4307281. PMID 25561237.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.